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The cyclin D2 gene is not expressed in resting primary B lymphocytes or in group I Burkitt’s lymphoma (BL)
cell lines that retain the characteristics of authentic BL cells. Expression of cyclin D2 is induced in primary B
lymphocytes following infection with Epstein-Barr virus (EBV) or transfection of the EBV genes EBNA-LP and
EBNA-2. However, attempts to induce cyclin D2 expression in BL cell lines by the enforced expression of EBV
genes were unsuccessful. Since the demethylation agent 5-azacytidine has been shown to modulate viral gene
expression in BL cells, we explored the possibility that methylation plays a significant role in the control of
cyclin D2 expression. We show that 5-azacytidine treatment of the Mutu Cl 179 BL cell line led to expression
of cyclin D2 RNA and that expression correlated with differences in the methylation status of a CCGG
restriction enzyme site near the transcription initiation region of the cyclin D2 gene. Thus, methylation appears
to play a direct role in the regulation of the cyclin D2 locus in BL.
The cyclin D family is involved in the control of both pro-
liferation and differentiation (12, 16, 18–20). We reported pre-
viously that the expression of cyclin D2 correlated with the
expression of the full set of Epstein-Barr virus (EBV) immor-
talizing genes in cell lines derived from Burkitt’s lymphoma
(BL) (17). Group I BL cell lines, which retain the phenotype
characteristic of BL in vivo and express a subset of the EBV
immortalizing genes, do not express cyclin D2, whereas group
III BL cells lines, which arise spontaneously from group I BL
cell lines and express the full complement of EBV immortal-
izing genes, express cyclin D2 RNA. This finding suggested
that the expression of EBV genes may regulate the expression
of cyclin D2, and we have since demonstrated this to be true
for primary B lymphocytes; infection with EBV or transfection
with two EBV genes, EBNA-LP and EBNA-2, results in the
induction of cyclin D2 expression (21). We investigated
whether the cyclin D2 gene could be regulated by EBV in the
same manner in BL cell lines.
Coexpression of EBNA-2 and EBNA-LP in group I BL cell
lines. The Mutu Cl 179 cell line displays the group I BL
phenotype, with EBV expression restricted to EBNA-1 and the
EBER RNAs (10), and no detectable cyclin D2 RNA is found
in this cell line (17). We introduced vectors for EBNA-LP and
EBNA-2 (21) into Mutu Cl 179 cells by electroporation (4) and
investigated whether cyclin D2 expression could be induced.
Western blotting (immunoblotting) of extracts from the trans-
fected cells confirmed that both viral proteins were expressed
(Fig. 1A). However, no cyclin D2 RNA was detectable in the
transfected cells as assayed by reverse transcription (RT)-PCR
(21). A PCR product was readily amplified from the Jijoye cell
line, which is known to express cyclin D2 (Fig. 1B). Recon-
struction experiments showed that the cyclin D2 signal could
be detected in a 103-fold dilution of the Jijoye RNA, demon-
strating the sensitivity of this assay (data not shown). The
integrity of the RNA was verified by amplifying a segment of
the cdc2 coding sequence.
We also attempted to induce the expression of cyclin D2 by
transfection of individual viral genes or following infection
with EBV. EBV-negative BL cell lines that had previously been
either infected (5) with EBV (BL41, BL41/P3HR1, and BL41/
B95-8) or transfected (9) with EBV genes (BJAB, BJAB-
EBNA-2, BJAB-EBNA-LP, BJAB-LMP1, BJAB-EBNA-1,
BJAB-EBNA-3a, and BJAB-EBNA-3C) were found to be neg-
ative for cyclin D2 expression. Thus, the introduction and sta-
ble expression of EBV genes was not sufficient to induce the
expression of cyclin D2 RNA in these established cell lines
(data not shown).
Methylation of the cyclin D2 locus in BL cells. Since these
results are in sharp contrast to our findings with primary B
lymphocytes, we decided to investigate the differences. One
possible explanation for the difference in the ability of EBV to
induce cyclin D2 in primary B lymphocytes and BL cell lines
was that alterations to the cyclin D2 locus in BL cell lines might
make this locus refractory to transactivation by EBV genes.
Southern blotting analysis using EcoRI and PstI revealed no
gross alterations in group I BL cell lines (Fig. 2). Since meth-
ylation has been shown to play a role in the silencing of many
viral genes in group I BL cells (1, 2, 6, 7, 11, 13–15, 22), we next
asked whether the cyclin D2 locus was differentially methylated
in cell lines that differ in their cyclin D2 expression. Two
subclones from the Mutu BL cell line, Mutu Cl 179 (group I)
and Mutu Cl 62 (group III), were chosen for this analysis since
these cell lines are isogenic yet display different phenotypes; Cl
179 has a quasi-resting phenotype, expresses a restricted set of
EBV genes (10), and has no detectable cyclin D2 RNA,
whereas Cl 62 has an activated phenotype, expresses the full
complement of EBV immortalizing genes, and also expresses
cyclin D2 RNA (17).
For comparison, we analyzed DNA from an EBV-immor-
talized cell line (LCL), from primary B lymphocytes isolated
from human peripheral blood (21), and from the two Mutu
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clones. The genomic DNAs were digested with the isoschi-
zomers HpaII and MspI, which differ in sensitivity to methyl-
ation at the second cytosine in the CCGG recognition site.
Figure 3A shows the expected cleavage pattern for these
enzymes based on the DNA sequence surrounding the tran-
scription start sites of the cyclin D2 gene (16a). Complete
digestion would generate a series of fragments ranging from
38 to 541 bp that would be detectable with a probe specific
for this region. However, the 156-, 144-, and 189-bp frag-
ments are unlikely to be resolved by electrophoresis in aga-
rose gels, and the smaller fragments would be undetectable
by Southern blotting. The primary B-lymphocyte and LCL
DNAs yielded two major products which we interpret to be
the 541-bp fragment (band 2 in Fig. 3B) and the mixed 156-,
144-, and 189-bp fragments (band 4, 5, and 6 in Fig. 3B). In
these cells, there appears to be no distinction between HpaII
and MspI. In both Mutu cell lines, an additional fragment of
about 700 bp was observed with HpaII but not MspI (band 1).
This is likely to reflect a methylation difference specific for BL.
Significantly, the group I BL cell line had another novel frag-
ment of about 300 bp which was not present in the group III
counterpart or in the primary B lymphocytes and the LCL
FIG. 1. Expression of EBNA-2 and EBNA-LP in group I BL. Mutu Cl 179
cells were transfected, in duplicate, with expression vectors for EBNA-2 and
EBNA-LP where indicated and harvested after 24 h (21). (A) Protein extracts
were prepared, separated on a sodium dodecyl sulfate–10% polyacrylamide gel,
and immunoblotted with monoclonal antibodies specific for EBNA-2 (PE-2;
Dako) or EBNA-LP (8). The positions of the EBNA-2- and EBNA-LP-specific
bands are indicated on the right. The sizes of markers (M) are indicated in
kilodaltons. (B) Total cell RNA was prepared from the transfected cells, and the
expression of cyclin D2 and cdc2 was determined by RT-PCR (21). The cyclin
D2-negative group I cell line Mutu Cl 179 and the cyclin D2-positive group III
BL cell line Jijoye were analyzed as controls. The primers GGCTCTTG
GAAATTGAGCGGA and AGGAACCCCTTCCTCTTCACT were used to de-
tect the cdc2 RNA. The positions of the cyclin D2- and cdc2-specific fragments
are indicated on the right. Sizes of markers (M) are indicated in nucleotides.
FIG. 2. Cyclin D2 locus in B-cell lines. DNA was prepared from the indicated
cell lines; 10 mg of DNA was digested with the restriction enzyme EcoRI or PstI,
separated on a 1% agarose gel, and Southern blotted. The cyclin D2-specific
fragments were identified by hybridization with the PstI-to-NcoI fragment
shown in Fig. 3A. The estimated sizes of the fragments are indicated on the
left.
FIG. 3. Methylation of the 59 region of cyclin D2. (A) Genomic organization
surrounding the cyclin D2 mRNA start site. The positions of the major RNA
start sites (16a) are indicated with arrows. The positions of the MspI (M) sites
and the PstI-to-NcoI fragment used as a probe are marked. (B) DNA was
prepared from the indicated cell lines and from primary B lymphocytes; 10 mg of
DNA was digested with the restriction enzymes HpaII (H) and MspI (M),
separated on a 1% agarose gel, and Southern blotted. The cyclin D2-specific
fragments were identified by hybridization with the PstI-to-NcoI fragment shown
in panel A. The positions of the molecular weight markers (in base pairs) are
shown on the left.
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(band 3). Since band 3 is shorter than the 541-bp MspI
fragment, it must be derived from methylation of either the
C or D restriction site near the start of transcription (Fig.
3A).
Effect of 5-azacytidine on cyclin D2 expression in group I
BL. To further investigate whether methylation is involved in
the regulation of cyclin D2 in these BL cell lines, we tested the
effect of the demethylating agent 5-azacytidine on the expres-
sion of cyclin D2 in the group I BL cell line Mutu Cl 179. This
agent has been previously shown to activate the expression of
methylated viral genes in a small fraction of treated cells (10,
14). Mutu Cl 179 cells were cultured with 15 mM 5-azacytidine
for 3 days, and the expression of cyclin D2 was determined by
using the RT-PCR assay (21). Cyclin D2 was detected in
Mutu Cl 179 only after treatment with 5-azacytidine,
whereas the control cdc-2 transcript was identified in both
samples (Fig. 4).
These data show that at least one site in the 59 flanking
region of cyclin D2 is hypermethylated in a group I BL com-
pared with a group III BL and that the difference in expression
of cyclin D2 is reflected by the differential methylation. We
propose that methylation of the 59 flanking region of cyclin D2
plays a role in silencing its expression in BL. The control of
gene expression by selective methylation has been observed for
a variety of differentiation of cell-type-specific cell genes (3)
and for EBV genes in BL (1, 2, 6, 7, 11, 13–15, 22). There is
evidence to suggest that methylation may play a direct role in
down regulating gene expression; for example, the methylation
of specific restriction enzyme sites in the LMP-1 promoter and
the Wp and Cp promoters reduces the level of their expression
(13, 15). However, it is also possible that methylation may play
a secondary role (3) in silencing gene expression. Since 5-aza-
cytidine treatment of Mutu Cl 179 also induces the expression
of viral genes, it is not possible to distinguish whether the
induction of cyclin D2 is a direct result of demethylation of the
flanking regions or if it also requires the expression of EBV
genes.
B lymphocytes in vivo are subject to different fates, depend-
ing on their antigen specificity, and can be selected to apop-
tose, to amplify and mutate the immunoglobulin genes, to
differentiate into antibody-secreting plasma cells, or to stop
dividing and become memory cells (23). A lack of monospecific
reagents has so far precluded the analysis of the normal pat-
tern of cyclin D2 expression during B-lymphocyte differentia-
tion in vivo. However, since members of the cyclin D2 family
influence both cell proliferation and differentiation (20), it is
likely that cyclin D2 plays a role in normal B-lymphocyte
differentiation. The close correlation between cyclin D2 ex-
pression and the activated B-cell phenotype suggests that
cyclin D2 expression is an integral component of B-lympho-
cyte activation. Although they proliferate, BL cells in vivo
display a quasi-resting phenotype, which implies that down
regulation of the activation phenotype is important for the
development of BL. The control of cyclin D2 expression by
differential methylation may therefore provide a selective
advantage to precursor BL cells during the development of
the lymphoma.
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